Disease · MONDO_0008903
lung cancer
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. lung cancer. Diseases, record MONDO_0008903. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0008903
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
adenocarcinoma of lung, response to tyrosine kinase inhibitor in, autosomal dominant, somatic mutation, adenocarcinoma of lung, somatic, cancer of lung, lung cancer, protection against, autosomal dominant, somatic mutation, lung cancer, resistance to, autosomal dominant, somatic mutation, lung cancer, somatic, lung cancer, susceptibility to, autosomal dominant, somatic mutation, malignant lung neoplasm, malignant lung tumor, malignant lung tumour, malignant neoplasm of lung, malignant neoplasm of the lung, malignant tumor of lung, malignant tumor of the lung, malignant tumour of lung, malignant tumour of the lung, nonsmall cell lung cancer, response to tyrosine kinase inhibitor in, autosomal dominant, somatic mutation, nonsmall cell lung cancer, somatic, nonsmall cell lung cancer, susceptibility to, autosomal dominant, somatic mutation
- Open Targets
Drugs261
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| ATEZOLIZUMAB | CHEMBL3707227 | Antibody | Approval | DailyMed | 12 | 11 | 11 | Drugs and targets |
| ETOPOSIDE | CHEMBL44657 | Small molecule | Approval | DailyMed | 11 | 10 | 10 | Drugs and targets |
| CEMIPLIMAB | CHEMBL4297723 | Antibody | Approval | DailyMed | 4 | 3 | 3 | Drugs and targets |
| ALECTINIB | CHEMBL1738797 | Small molecule | Approval | TTD | 3 | 2 | 2 | Drugs and targets |
| METHOTREXATE SODIUM | CHEMBL3244648 | Small molecule | Approval | DailyMed | 1 | 0 | 0 | Drugs and targets |
| OLMUTINIB | CHEMBL3786343 | Small molecule | Approval | TTD | 1 | 0 | 0 | Drugs and targets |
| PRINOMASTAT | CHEMBL75094 | Small molecule | Approval | TTD | 1 | 0 | 0 | Drugs and targets |
| TRAMETINIB DIMETHYL SULFOXIDE | CHEMBL2105741 | Small molecule | Approval | DailyMed | 1 | 0 | 0 | Drugs and targets |
| PEMBROLIZUMAB | CHEMBL3137343 | Antibody | Phase 3 | ClinicalTrials.gov | 34 | 34 | 34 | Drugs and targets |
| PACLITAXEL | CHEMBL428647 | Small molecule | Phase 3 | ClinicalTrials.gov | 35 | 33 | 30 | Drugs and targets |
1 to 10 of 261
See all 261 drugsTargets307
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| EGFR | Epidermal growth factor receptor | 17 | Epidermal growth factor receptor erbB1 inhibitor | Approval | https://conductscience.org/library/genes/1956 | Drugs and targets |
| KDR | Vascular endothelial growth factor receptor | 14 | Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/3791 | Drugs and targets |
| FLT4 | Vascular endothelial growth factor receptor | 11 | Vascular endothelial growth factor receptor 3 inhibitor; Vascular endothelial growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/2324 | Drugs and targets |
| FLT1 | Vascular endothelial growth factor receptor | 10 | Vascular endothelial growth factor receptor 1 inhibitor; Vascular endothelial growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/2321 | Drugs and targets |
| PDCD1 | Programmed cell death protein 1 | 10 | Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor | Approval | https://conductscience.org/library/genes/5133 | Drugs and targets |
| PDGFRB | Platelet-derived growth factor receptor | 9 | Platelet-derived growth factor receptor beta inhibitor; Platelet-derived growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/5159 | Drugs and targets |
| KIT | Mast/stem cell growth factor receptor Kit | 8 | Stem cell growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/3815 | Drugs and targets |
| ERBB2 | Receptor tyrosine-protein kinase erbB-2 | 6 | Receptor protein-tyrosine kinase erbB-2 inhibitor | Phase 2 | https://conductscience.org/library/genes/2064 | Drugs and targets |
| FGFR1 | Fibroblast growth factor receptor | 6 | Fibroblast growth factor receptor 1 inhibitor; Fibroblast growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/2260 | Drugs and targets |
| MAP2K1 | Dual specificity mitogen-activated protein kinase kinase 1 | 6 | Dual specificity mitogen-activated protein kinase kinase 1 inhibitor; Dual specificity mitogen-activated protein kinase kinase; MEK1/2 inhibitor | Approval | https://conductscience.org/library/genes/5604 | Drugs and targets |
1 to 10 of 307
See all 307 targetsTrials298
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 7 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00981058 | First-line Treatment of Participants With Stage IV Squamous Non-Small Cell Lung Cancer With Necitumumab and Gemcitabine-Cisplatin | Phase 3 | 1,093 | 2016-06-27 | Non Small Cell Lung Cancer | CISPLATIN, GEMCITABINE, NECITUMUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT03676192 | To Compare Efficacy and Safety of CT-P16 and European Union-Approved Avastin as First-Line Treatment for Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer | Phase 3 | 689 | 2025-03-17 | Adenocarcinoma of Lung | BEVACIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02031458 | A Study of Atezolizumab in Participants With Programmed Death - Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer | Phase 2 | 667 | 2017-03-23 | Non-Small Cell Lung Cancer | ATEZOLIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT05091567 | A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer | Phase 3 | 660 | 2025-12-29 | Small-Cell Lung Cancer | ATEZOLIZUMAB, LURBINECTEDIN | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT02998528 | A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC) | Phase 3 | 505 | 2022-09-28 | Non Small Cell Lung Cancer | CARBOPLATIN, CISPLATIN, DOCETAXEL, GEMCITABINE, IPILIMUMAB, NIVOLUMAB, PACLITAXEL, PEMETREXED, VINORELBINE | Its record names the disease | ClinicalTrials.gov |
| NCT04623775 | A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC) | Phase 2 | 468 | 2025-03-18 | Non-small Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer | NIVOLUMAB, RELATLIMAB | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT02152631 | A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer | Phase 3 | 453 | 2018-12-12 | Non Small Cell Lung Cancer | ABEMACICLIB, ERLOTINIB | Its record names the disease | ClinicalTrials.gov |
| NCT00527735 | Phase II Study for Previously Untreated Subjects With Non Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC) | Phase 2 | 334 | 2012-07-16 | Lung Cancer, Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung | CARBOPLATIN, IPILIMUMAB, PACLITAXEL | Its record names the disease | ClinicalTrials.gov |
| NCT01935336 | Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers | Phase 2 | 171 | 2022-02-11 | Adenocarcinoma of the Lung, Extensive Stage Small Cell Lung Cancer, Limited Stage Small Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Recurrent Small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer | PONATINIB HYDROCHLORIDE | Its record names the disease | ClinicalTrials.gov |
| NCT01434342 | Feasibility of Delivering a Quitline Based Smoking Cessation Intervention in Cancer Patients | Early phase 1 | 146 | 2017-06-06 | Lung Cancer, Tobacco Use Disorder, Breast Cancer, Colorectal Cancer, Prostate Cancer | (+/-)NICOTINE, NICOTINE | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 298
See all 298 trialsComparisons in its trials42
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Necitumumab + Gemcitabine + Cisplatin vs Gemcitabine + Cisplatin: deaths from any cause | 476 of 538 | 487 of 541 | 1,079 | NCT00981058 | Trial comparisons |
| Necitumumab + Gemcitabine + Cisplatin vs Gemcitabine + Cisplatin: serious adverse events | 262 of 538 | 208 of 541 | 1,079 | NCT00981058 | Trial comparisons |
| CT-P16 vs Avastin: deaths from any cause | 24 of 345 | 25 of 344 | 689 | NCT03676192 | Trial comparisons |
| CT-P16 vs Avastin: serious adverse events | 69 of 345 | 73 of 344 | 689 | NCT03676192 | Trial comparisons |
| Atezolizumab vs Atezolizumab+ Lurbinectedin: Randomized Phase: Number of Participants With Anti-Drug Antibodies (ADAs) to Atezolizumab | 20 of 239 | 19 of 242 | 481 | NCT05091567 | Trial comparisons |
| Abemaciclib vs Erlotinib: deaths from any cause | 186 of 265 | 123 of 175 | 440 | NCT02152631 | Trial comparisons |
| Abemaciclib vs Erlotinib: serious adverse events | 112 of 265 | 43 of 175 | 440 | NCT02152631 | Trial comparisons |
| Arm B: Platinum Doublet Chemo vs Arm C: Nivo 360 mg + Platinum Doublet Chemo: Major Pathologic Response (MPR) Rate | 16 of 179 | 66 of 179 | 358 | NCT02998528 | Trial comparisons |
| Arm B: Platinum Doublet Chemo vs Arm C: Nivo 360 mg + Platinum Doublet Chemo: Pathologic Complete Response (pCR) Rate | 4 of 179 | 43 of 179 | 358 | NCT02998528 | Trial comparisons |
| Part 1: Treatment A vs Part 1: Treatment B: Number of Participants With a Treatment Related AEs in Part 1 | 75 of 77 | 76 of 79 | 156 | NCT04623775 | Trial comparisons |
1 to 10 of 42
See all 42 comparisons in its trialsPapers from its trials166
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0008903
GET https://conductscience.org/api/diseases/v1/MONDO_0008903/drugs?page=2